Friday, August 21, 2026
GlobeNewsInfo Logo
Home / Business & Corporate / Anuh Pharma expands manufacturing footprint with acquisition of Vanquest Pharma facility

Anuh Pharma expands manufacturing footprint with acquisition of Vanquest Pharma facility

Published on
Anuh Pharma expands manufacturing footprint with acquisition of Vanquest Pharma facility
Image used for illustrative purposes only. GlobeNewsInfo / Visuals

Anuh Pharma Limited has signed an asset transfer agreement to acquire a manufacturing plant from Vanquest Pharma Private Limited for Rs. 729 million. The transaction aims to boost production capacity by 525 metric tonnes per annum for active pharmaceutical ingredients and intermediates.

INDIA —Anuh Pharma Limited has executed an asset transfer agreement to acquire a manufacturing facility located in Tarapur, Maharashtra, from Vanquest Pharma Private Limited. Valued at Rs. 729 million, the cash-based transaction encompasses land, buildings, and plant machinery dedicated to the production of active pharmaceutical ingredients and pharmaceutical intermediates. The acquisition is projected to scale up the company's manufacturing output by 525 metric tonnes per annum. Both entities structured the deal as an arm's length transaction involving independent parties, with no cross-shareholdings or related-party affiliations.

Headquartered in Mumbai, India, Anuh Pharma Limited is an established pharmaceutical enterprise specializing in the manufacture of active pharmaceutical ingredients and chemical intermediates. The strategic addition of this manufacturing site directly addresses scaling requirements, allowing the firm to capture higher volume demands within competitive domestic and international markets. By integrating existing infrastructure rather than commissioning greenfield construction, the company accelerates operational readiness for its core pharmaceutical product lines.

For the broader pharmaceutical manufacturing sector, the transaction highlights an industry trend toward consolidating operational assets to optimize production capabilities. Regional pharmaceutical hubs in Maharashtra continue to attract capital investments aimed at expanding chemical synthesis and bulk drug capacities. Securing ready-to-use industrial units minimizes regulatory lead times and construction delays associated with setting up new chemical processing plants.

Market participants and institutional investors view the capital allocation of Rs. 729 million as a strategic move to reinforce long-term operational scale without equity dilution. Because the transaction relies entirely on cash consideration without issuing new shares, existing equity structures remain unaffected. Decision-makers monitoring the sector will look to similar asset transfers as an efficient mechanism for expanding production capacity and supply chain resilience within the chemical and pharmaceutical industries.

About GlobeNewsInfo

GlobeNewsInfo is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.

More on Business & Corporate

Latest Business News

Share this Article

Just In
11 hours ago Oman Investment Authority ties Chinese capital to local industry in record agreement package 12 hours ago JBIC raises financing ceiling to USD 283 million for US crude oil export infrastructure 12 hours ago BAE Systems wins 138 million USD Navy award to sustain Virginia-class propulsor output through 2032 12 hours ago Hyundai Engineering deepens Texas solar exposure with second OCI Energy project acquisition